USPTO serial 99556326
AOB PHARMA
Reviewed by CopyMark Law Group
Status 661
- Filing date
- Status date
- Registration date
- —
- Examiner
- STURMAN, JOSHUA M
- Law office
- TMEG LAW OFFICE 103
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AOB PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
CAMBRIDGE, MA, US
Cambridge, MA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nathan Timothy Harris
Nathan Timothy Harris LANDO & ANASTASI, LLP60 State Street, 23rd FloorBoston, MA 02109United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Creams for cosmetic purposes; cosmetic preparations for body care; cosmetic preparations for skin care; hair care preparations; hair cleaning preparations; hair shampoos; hair conditioners; spray skin care products being non-medicated skin care preparations; cosmetics; tissues impregnated with cosmetic lotions; tissues impregnated with make-up removing preparations; paper towels in the nature of wipes impregnated with skin cleansing fluid; cosmetic toner; deodorants for human beings or for animals; gels for cosmetic purposes; pre-moistened cosmetic wipes, towelettes and tissues; cosmetic skin fresheners; non-medicated gels for skin care; non-medicated creams for skin care; bath preparations, not for medical purposes; cosmetic preparations for baths | ACTIVE | — |
| 005 | Medicated gels, creams, sprays and nasal sprays for therapeutic use in the nature of therapeutic pharmaceuticals containing ammonia oxidizing bacteria for the treatment of inflammatory diseases, for the treatment of systemic diseases, namely, hypertension, other cardiovascular and circulatory disorders, and primary and secondary headache disorders including migraine, and to counteract skin damage caused by UV exposure or aging; topical applications in the nature of gels, creams, sprays, and liquids for therapeutic use, namely, topical preparations containing ammonia oxidizing bacteria for the treatment of skin disorders, acne, inflammation, eye disorders, migraines, headaches, allergic reactions, insomnia, hypertension, thermoregulation, and to promote wound healing; medicated liquids for therapeutic use in the nature of therapeutic pharmaceuticals for the treatment of inflammatory diseases, for the treatment of systemic diseases, namely, hypertension, other cardiovascular and circulatory disorders, and primary and secondary headache disorders including migraine, and to counteract skin damage caused by UV exposure or aging; biological therapeutics being pharmaceutical preparations for treatment of skin disorders, circulatory and cardiovascular disorders, neurologic diseases, inflammation, gastrointestinal disorders, respiratory disorders, eye disorders, urogenital disorders, auditory disorders, migraines, headaches, allergic rhinitis, insomnia, hyperhidrosis, acne, and hypertension; therapeutic agents for thermoregulation and promoting wound healing | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 4, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 4, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 4, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 29, 2026 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jul 29, 2026 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jul 8, 2026 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| May 4, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 4, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 4, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 22, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 9, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 5, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 5, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 5, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 18, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 18, 2025 | NWAP | NEW APPLICATION ENTERED | — |